Loading…
Mangalam Drugs and Organics (MANGALAM)₹29.22−1.72%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Mangalam Drugs and Organics reported sales of ₹57.02 Cr, down 0.2% from Jun 2025, and net profit of −₹7.67 Cr. For the year to Mar 2026, sales were ₹232 Cr and net profit −₹44.18 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 97.26 | 102 | 76.42 | 79.86 | 88.63 | 72.71 | 57.11 | 49.48 | 58.32 | 67.18 | 57.02 |
| Expenses | 90.23 | 90.54 | 68.24 | 71.23 | 79.81 | 62.81 | 61.80 | 52.37 | 59.87 | 72.84 | 56.19 |
| Operating Profit | 7.00 | 11.72 | 8.22 | 8.73 | 8.79 | 9.94 | −4.64 | −2.85 | −1.55 | −5.63 | 0.92 |
| OPM % | 7.2% | 11.4% | 10.7% | 10.8% | 9.9% | 13.6% | −8.1% | −5.8% | −2.6% | −8.4% | 1.6% |
| Other Income | 0.00 | 0.06 | 0.03 | 0.15 | 0.15 | 0.48 | 0.15 | 0.04 | 0.23 | 0.10 | 0.12 |
| Interest | 3.32 | 3.96 | 3.76 | 3.68 | 3.50 | 4.04 | 4.05 | 5.05 | 4.06 | 3.09 | 3.69 |
| Depreciation | 3.64 | 3.87 | 3.89 | 3.98 | 4.06 | 4.71 | 4.49 | 4.64 | 4.47 | 4.67 | 4.10 |
| Profit before tax | 0.03 | 3.92 | 0.57 | 1.19 | 1.36 | 1.63 | −12.98 | −12.44 | −9.81 | −13.25 | −6.74 |
| Tax % | −1,150.0% | 10.2% | −362.1% | −124.2% | 5.8% | 95.7% | 6.1% | −41.1% | 0.0% | 1.1% | 13.2% |
| Net Profit | 0.51 | 3.54 | 2.69 | 2.70 | 1.30 | 0.07 | −13.85 | −7.37 | −9.88 | −13.47 | −7.67 |
| EPS (Rs) | 0.31 | 2.22 | 1.68 | 1.69 | 0.81 | 0.03 | −8.68 | −4.62 | −6.20 | −8.45 | −4.81 |
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| Sales | 368 | 318 | 232 | 232 |
| Expenses | 351 | 282 | 247 | 241 |
| Operating Profit | 17.04 | 36.13 | −15.04 | −9.11 |
| OPM % | 4.7% | 11.0% | −6.0% | −3.9% |
| Other Income | 0.00 | 0.00 | 1.01 | 0.49 |
| Interest | 14.04 | 15.04 | 16.06 | 15.89 |
| Depreciation | 15.04 | 17.04 | 18.04 | 17.88 |
| Profit before tax | −10.98 | 4.99 | −48.93 | −42.24 |
| Tax % | −18.0% | −41.0% | −9.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | — |
| Net Profit | −9.03 | 7.03 | −44.18 | −38.39 |
| EPS (Rs) | −5.71 | 4.23 | −27.96 | −24.08 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | — |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 15.98 | 15.98 | 15.99 |
| Reserves | 120 | 133 | 86.95 |
| Borrowings | 107 | 95.89 | 105 |
| Other Liabilities | 90.56 | 120 | 105 |
| Total Liabilities | 333 | 365 | 314 |
| Fixed Assets | 148 | 163 | 159 |
| CWIP | 7.99 | 2.99 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| Other Assets | 177 | 200 | 156 |
| Inventories | 124 | 140 | 103 |
| Trade receivables | 27.99 | 39.01 | 40.01 |
| Cash & equivalents | 1.01 | 3.01 | 1.01 |
| Total Assets | 333 | 365 | 314 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | 4.01 | 42.98 | 4.01 |
| Cash from investing activity | −12.04 | −19.08 | −12.03 |
| Cash from financing activity | 5.01 | −22.04 | 6.01 |
| Net cash flow | −3.01 | 0.99 | −1.99 |
| Capex | 11.79 | 20.13 | 11.86 |
| Free cash flow | −7.99 | 23.01 | −8.01 |
| CFO / OP % | 23.0% | 117.9% | −30.1% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 28 | 45 | 63 |
| Inventory days | 184 | 302 | 238 |
| Days payable | 99 | 199 | 177 |
| Cash conversion cycle | 112 | 148 | 125 |
| Working capital days | 12 | 6 | −64 |
| ROCE % | — | 8.0% | −14.0% |
For the Jun 2026 quarter, Mangalam Drugs and Organics reported sales of ₹57.02 Cr, down 0.2% year on year and net profit of −₹7.67 Cr. The operating margin was 1.6%.
Mangalam Drugs and Organics' sales for the year to Mar 2026 were ₹232 Cr; over the last twelve months they were ₹232 Cr.
Net profit for the year to Mar 2026 was −₹44.18 Cr, and −₹38.39 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−24.08.
Mangalam Drugs and Organics reported borrowings of ₹105 Cr at Mar 2026, against cash and equivalents of ₹1.01 Cr.
Cash from operations was ₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹8.01 Cr.